Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

STEEL: A Randomized Phase II Trial of Salvage Radiotherapy With Standard vs Enhanced Androgen Deprivation Therapy (With Enzalutamide) in Patients With Post-Prostatectomy PSA Recurrences With Aggressive Disease Features

NCT03809000 is registered in ClinicalTrials.gov with RTOG Foundation, Inc. as lead sponsor.

NCT NCT03809000
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03809000 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
STEEL: A Randomized Phase II Trial of Salvage Radiotherapy With Standard vs Enhanced Androgen Deprivation Therapy (With Enzalutamide) in Patients With Post-Prostatectomy PSA Recurrences With Aggressive Disease Features
Lead sponsor
RTOG Foundation, Inc.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
April 15, 2019
Completion date
September 15, 2029
Enrollment
188 (actual)
Sites
108

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer